Zepzelca
(Lurbinectedin)ApprovedSmall molecule
Jazz PharmaceuticalsLurbinectedin is used to treat certain types of lung cancer and ovarian cancer that have not responded to other treatments. It works by damaging cancer cell DNA to stop the cancer from growing.[2] Zepzelca is currently approved and in use across 18 indications[4].[1]
Zepzelca is one of 333 small molecule programs targeting Leiomyosarcoma. It is currently in Approved.
18
Indications
52
Total Trials
29
Active Trials
332
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zepzelca
Jazz PharmaceuticalsApproved
Adenocard
AstellasPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer8 trials
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Not yet recruiting·—·Phase 1/2·NCT07141771·100 enrolled
Show 5 more trials
Lung Cancer3 trials
Ewing sarcoma3 trials
Ovarian Cancer2 trials
31 more indications
Patients With Advanced Solid Tumors2 trials
Soft Tissue Sarcoma2 trials
Small Cell Lung Cancer ( SCLC )2 trials
Metastatic Colorectal Cancer1 trial
First Line Therapy1 trial
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Not yet recruiting·—·Phase 2·NCT06501976·9 enrolled
Non-Small Cell Lung Cancer1 trial
Patients With Solid Tumors1 trial
Selected Advanced Solid Tumors1 trial
Cardiac Repolarization1 trial
Leiomyosarcoma1 trial
Efficacy and Safety1 trial
Immune Checkpoint Inhibition1 trial
Advanced or Metastatic Solid Tumors1 trial
Relapse1 trial
Solid Tumors1 trial
Malignant Pleural Mesothelioma1 trial
Treatment1 trial
Neuroendocrine Cancer1 trial
Desmoplastic Small Round Cell Tumor1 trial
Small Cell Lung Carcinoma1 trial
Small Cell Carcinoma1 trial
Platinum-Resistant Lung Small Cell Carcinoma1 trial
Extensive-stage Small-cell Lung Cancer1 trial
Gastrointestinal1 trial
Carcinoma, Small Cell Lung1 trial
Regulatory
FDA Approval Timeline[5]
Jun 15, 2020
ZEPZELCA
NDA NDA213702
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zepzelca drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Lurbinectedin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company